EFFICACY OF ERLOTINIB FOR CNS RELAPSE AFTER GEFITINIB TREATMENT IN NON SMALL CELL LUNG CANCER PATIENTS

被引：0
|
作者：
Yanagitani, N. [1 ]
Sakatani, T. [1 ]
Saito, R. [1 ]
Tanaka, H. [1 ]
Kaburaki, K. [1 ]
Kudo, K. [1 ]
Ohyanagi, F. [1 ]
Horiike, A. [1 ]
Horai, T. [1 ]
Nishio, M. [1 ]
机构：
[1] Japanese Fdn Canc Res, Thorac Oncol Ctr, Canc Inst Hosp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [41] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
    Wong, Matthew K.
    Lo, Alvis I.
    Lam, Bing
    Lam, W. K.
    Ip, Mary S.
    Ho, James C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1023 - 1028
  • [42] Erlotinib as salvage treatment after failure to first-line gefitinib in Non-Small Cell Lung Cancer
    Wong, King Yan Matthew
    Lo, Alvis
    Lam, Jamie
    Lam, Bing
    Ip, Mary S.
    Ho, James C.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S719 - S719
  • [43] Prospective Assesment of Combined Pemetrexed and Erlotinib or Gefitinib Therapy After the Relapse to Erlotinib or Gefitinib in Patients With Advanced Non-Small Cell Lung Cancer Having an Active Epidermal Growth Factor Receptor Mutation
    Okishio, K.
    Yoshimura, N.
    Kimura, T.
    Daga, H.
    Takeda, K.
    Kawaguchi, T.
    Kobayashi, M.
    Hirashima, T.
    Hirata, K.
    Kudoh, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S628 - S629
  • [44] Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    He, Chunxiao
    Zhang, Beibei
    Zhang, Yiping
    JOURNAL OF THORACIC DISEASE, 2013, 5 (04) : 400 - 405
  • [45] Cea As A Negative Predictive Factor For Patients With Non-Small Cell Lung Cancer Under Gefitinib Or Erlotinib Treatment
    Fang, Y. -H.
    Lin, Y. -C.
    Ying-Huang, T.
    Hung, M. -S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [46] Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer
    Shin, Hong-Joon
    Kim, Tae-Ok
    Kang, Hyun-Wook
    Chi, Su-Young
    Ban, Hee-Jung
    Kim, Soo-Ok
    Kwon, Yong-Soo
    Oh, In-Jae
    Kim, Kyu-Sik
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2011, 71 (01) : 15 - 23
  • [47] Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
    Kaira, Kyoichi
    Naito, Tateaki
    Takahashi, Toshiaki
    Ayabe, Eriko
    Shimoyama, Rai
    Kaira, Rieko
    Ono, Akira
    Igawa, Satoshi
    Shukuya, Takehito
    Murakami, Haruyasu
    Tsuya, Asuka
    Nakamura, Yukiko
    Endo, Masahiro
    Yamamoto, Nobuyuki
    LUNG CANCER, 2010, 68 (01) : 99 - 104
  • [48] Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
    Yoshida, Tsukasa
    Yamada, Kazuhiko
    Azuma, Koichi
    Kawahara, Akihiko
    Abe, Hideyuki
    Hattori, Satoshi
    Yamashita, Fumie
    Zaizen, Yoshiaki
    Kage, Masayoshi
    Hoshino, Tomoaki
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [49] Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
    Tsukasa Yoshida
    Kazuhiko Yamada
    Koichi Azuma
    Akihiko Kawahara
    Hideyuki Abe
    Satoshi Hattori
    Fumie Yamashita
    Yoshiaki Zaizen
    Masayoshi Kage
    Tomoaki Hoshino
    Medical Oncology, 2013, 30
  • [50] Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation
    Kim, H.
    Kim, Y.
    Oh, S.
    Seo, M.
    Lee, S.
    Kim, D.
    Heo, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345